XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

Core Insights - Recent research has identified 410 genetic factors associated with gout, including 149 new factors, which supports the link between genetic predisposition and the over-expression of xanthine oxidase (XO) in gout and related diseases [3] - XORTX Therapeutics is focused on developing therapies that inhibit XO to treat gout and progressive kidney diseases, leveraging these genetic insights to guide treatment decisions [4][10] Company Updates - XORTX has appointed Krysta Davies Foss as a director, bringing over 25 years of experience in biotechnology and pharmaceutical strategy [5][6] - The company clarified details regarding a US$1.1 million Registered Direct Offering, correcting the number of pre-funded warrants issued [7] - XORTX is in the process of acquiring the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems, with a closing date expected by January 13, 2026, pending ASX approval [8]